N-803, an interleukin-15 superagonist, was studied in combination with nivolumab in metastatic NSCLC [82], and is currently being investigated in combination with PD-1/PD-L1 agents in the setting of advanced solid tumors (including SCLC) that have progressed on or after single-agent checkpoint inhibitor in the QUILT-3.055 trial (NCT03228667). Here, CD274 is linked to small cell lung carcinoma.